Wistar Wire: Genes

wistar
A BRAF inhibitor known as vemurafenib (Zelboraf) has been touted as a breakthrough melanoma treatment. But for some patients, the price of success is a mutation that leads to the development of secondary skin cancers called squamous cell carcinomas. In an editorial in The New England Journal of Medicine, Wistar researcher Ashani Weeraratna, Ph.D., discusses the success of a new combination treatment.
Cancer, Genes, Melanoma
wistar
A news segment featuring Wistar Professor Louise C. Showe, Ph.D., aired on CBS3 on December 21, 2011 in the five o'clock broadcast. The segment discussed her work toward developing a blood test for lung cancer.
Cancer, Genes
wistar
One reason why lung cancer is one of the deadliest forms of cancer in the United States is that it is so difficult to detect at its earliest stages, when treatment is most effective. But what if a simple blood test—no more invasive than having your cholesterol or blood sugar levels checked—could do the trick?
Cancer, Genes
wistar
Hui Hu, Ph.D., an assistant professor in Wistar's immunology program, was awarded the 2011 Young Investigator Award in Cell and Gene Therapy for Cancer from the Alliance for Cancer Gene Therapy.
Cancer, Genes